226 related articles for article (PubMed ID: 33112294)
41. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
[TBL] [Abstract][Full Text] [Related]
42. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review].
Ito Y; Suzuki S; Ito K; Imai T; Okamoto T; Kitano H; Sugitani I; Sugino K; Tsutsui H; Hara H; Yoshida A; Shimizu K
Endocr J; 2016 Jul; 63(7):597-602. PubMed ID: 27210070
[TBL] [Abstract][Full Text] [Related]
43. Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Pan P; Wang L; Wang Y; Shen L; Zheng P; Bi C; Zhang A; Lv Y; Xue Z; Sun M; Sun C; Li J; Jin L; Yao Y
Acta Haematol; 2020; 143(3):204-216. PubMed ID: 31514197
[TBL] [Abstract][Full Text] [Related]
44. Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma.
Srinivas S; Stein D; Teltsch DY; Tao S; Cisar L; Ramaswamy K
J Oncol Pharm Pract; 2018 Dec; 24(8):574-583. PubMed ID: 28732453
[TBL] [Abstract][Full Text] [Related]
45. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
[TBL] [Abstract][Full Text] [Related]
46. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
47. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.
Li J; Gu J
Eur J Clin Pharmacol; 2017 Oct; 73(10):1209-1217. PubMed ID: 28710508
[TBL] [Abstract][Full Text] [Related]
48. Microcystin-LR induced thyroid dysfunction and metabolic disorders in mice.
Zhao Y; Xue Q; Su X; Xie L; Yan Y; Steinman AD
Toxicology; 2015 Feb; 328():135-41. PubMed ID: 25497113
[TBL] [Abstract][Full Text] [Related]
49. [Expert consensus on the management of adverse events of ErbB family tyrosine kinase inhibitors in breast cancer].
Wang BY; Ge R; Jiang ZF;
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):798-806. PubMed ID: 33113620
[TBL] [Abstract][Full Text] [Related]
50. Medical monitoring in patients with bipolar disorder: a review of data.
Fagiolini A
J Clin Psychiatry; 2008 Jun; 69(6):e16. PubMed ID: 18683991
[TBL] [Abstract][Full Text] [Related]
51. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
52. [Endocrine complications of modern cancer therapy].
Čáp J
Vnitr Lek; 2016; 62(9 Suppl 3):45-49. PubMed ID: 27734691
[TBL] [Abstract][Full Text] [Related]
53. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.
Sodergren SC; White A; Efficace F; Sprangers M; Fitzsimmons D; Bottomley A; Johnson CD
Crit Rev Oncol Hematol; 2014 Jul; 91(1):35-46. PubMed ID: 24495942
[TBL] [Abstract][Full Text] [Related]
54. Changes in Lipid Indices in HIV+ Cases on HAART.
Ji S; Xu Y; Han D; Peng X; Lu X; Brockmeyer NH; Wu N
Biomed Res Int; 2019; 2019():2870647. PubMed ID: 30868068
[TBL] [Abstract][Full Text] [Related]
55. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic.
Ross DS; Daniels GH; Gouveia D
J Clin Endocrinol Metab; 1990 Sep; 71(3):764-9. PubMed ID: 2394778
[TBL] [Abstract][Full Text] [Related]
56. Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?
Pani F; Massidda M; Pusceddu V; Puzzoni M; Massa E; Madeddu C; Scartozzi M; Mariotti S
Eur J Endocrinol; 2017 Jul; 177(1):85-92. PubMed ID: 28468766
[TBL] [Abstract][Full Text] [Related]
57. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
[TBL] [Abstract][Full Text] [Related]
58. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Papaetis GS; Syrigos KN
BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
[TBL] [Abstract][Full Text] [Related]
59. Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology.
Shah RR; Shah DR
Drug Saf; 2019 Feb; 42(2):181-198. PubMed ID: 30649743
[TBL] [Abstract][Full Text] [Related]
60. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
